{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:24:22Z","timestamp":1787772262890,"version":"build-2784847793"},"reference-count":48,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2022,9,29]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>There has been limited systematic evaluation of outcomes and drivers of inappropriate non-vitamin K antagonist oral anticoagulants (NOACs) dosing among patients with atrial fibrillation (AF). This review identified and systematically evaluated literature on clinical and economic outcomes of inappropriate NOAC dosing and associated patient characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>MEDLINE, Embase, Cochrane Library, International Pharmaceutical Abstracts, Econlit, PubMed and NHS EEDs databases were searched for English language observational studies from all geographies published between 2008 and 2020, examining outcomes of, or factors associated with, inappropriate NOAC dosing in adult patients with AF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>One hundred and six studies were included in the analysis. Meta-analysis showed that compared with recommended NOAC dosing, off-label underdosing was associated with a null effect on stroke outcomes (ischaemic stroke and stroke\/transient ischaemic attack (TIA), stroke\/systemic embolism (SE) and stroke\/SE\/TIA). Meta-analysis of 15 studies examining clinical outcomes of inappropriate NOAC dosing found a null effect of underdosing on bleeding outcomes (major bleeding HR=1.04, 95%\u2009CI 0.90 to 1.19; p=0.625) but an increased risk of all-cause mortality (HR=1.28, 95%\u2009CI 1.10 to 1.49; p=0.006). Overdosing was associated with an increased risk of major bleeding (HR=1.41, 95%\u2009CI 1.07 to 1.85; p=0.013). No studies were found examining economic outcomes of inappropriate NOAC dosing. Narrative synthesis of 12 studies examining drivers of inappropriate NOAC dosing found that increased age, history of minor bleeds, hypertension, congestive heart failure and low creatine clearance (CrCl) were associated with an increased risk of underdosing. There was insufficient evidence to assess drivers of overdosing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our analysis suggests that off-label underdosing of NOACs does not reduce bleeding outcomes. Patients prescribed off-label NOAC doses are at an increased risk of all-cause mortality. These data underscore the importance of prescriber adherence to NOAC dosing guidelines to achieve optimal clinical outcomes for patients with AF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PROSPERO registration number<\/jats:title>\n                  <jats:p>CRD42020219844.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2022-321114","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T13:20:36Z","timestamp":1667222436000},"page":"178-185","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":54,"title":["Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"109","author":[{"given":"Valeria","family":"Caso","sequence":"first","affiliation":[{"name":"Stroke Unit, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris R","family":"de Groot","sequence":"additional","affiliation":[{"name":"Heart Center, Department of Cardiology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5469-4579","authenticated-orcid":false,"given":"Marcelo","family":"Sanmartin Fernandez","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Ramon y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3625-0987","authenticated-orcid":false,"given":"Tom\u00e1s","family":"Segura","sequence":"additional","affiliation":[{"name":"Deparment of Neurology, Hospital General Universitario de Albacete, Albacete, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Blomstr\u00f6m-Lundqvist","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, \u00d6rebro University, Orebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hargroves","sequence":"additional","affiliation":[{"name":"Stroke Medicine, East Kent Hospitals University NHS Foundation Trust, Canterbury, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotiris","family":"Antoniou","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Williams","sequence":"additional","affiliation":[{"name":"South East London Integrated Card Systemt, and UCLPartners, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Worsley","sequence":"additional","affiliation":[{"name":"Wickenstones, Carlow, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Harris","sequence":"additional","affiliation":[{"name":"Wickenstones, Carlow, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4968-4952","authenticated-orcid":false,"given":"Amrit","family":"Caleyachetty","sequence":"additional","affiliation":[{"name":"Wickenstones, Carlow, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Vardar","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Field","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian T","family":"Ruff","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Deparmtent of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"2025100705500383000_109.3.178.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"2025100705500383000_109.3.178.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"2025100705500383000_109.3.178.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"2025100705500383000_109.3.178.4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017559"},{"key":"2025100705500383000_109.3.178.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"2025100705500383000_109.3.178.6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-031341"},{"key":"2025100705500383000_109.3.178.7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"2025100705500383000_109.3.178.8","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004672","article-title":"Suboptimal use of non-vitamin K antagonist oral anticoagulants: results from the RAMSES study","volume":"95","author":"Ba\u015faran","year":"2016","journal-title":"Medicine"},{"key":"2025100705500383000_109.3.178.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.joa.2016.11.003"},{"key":"2025100705500383000_109.3.178.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.09.966"},{"key":"2025100705500383000_109.3.178.11","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01220","article-title":"Appropriateness of DOAC prescribing before and during hospital admission and analysis of determinants for inappropriate prescribing","volume":"9","author":"Moudallel","year":"2018","journal-title":"Front Pharmacol"},{"key":"2025100705500383000_109.3.178.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.03.600"},{"key":"2025100705500383000_109.3.178.13","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007633","article-title":"Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (the outcomes registry for better informed treatment of atrial fibrillation II)","volume":"7","author":"Steinberg","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2025100705500383000_109.3.178.14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-58665-5","article-title":"Effectiveness and safety of off-label dosing of non\u2013vitamin K antagonist anticoagulant for atrial fibrillation in Asian patients","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"},{"key":"2025100705500383000_109.3.178.15","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014177","article-title":"Label adherence of direct oral anticoagulants dosing and clinical outcomes in patients with atrial fibrillation","volume":"9","author":"Yu","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025100705500383000_109.3.178.16","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2459\/JCM.0000000000001043","article-title":"Inappropriate dose of nonvitamin-K antagonist oral anticoagulants: prevalence and impact on clinical outcome in patients with nonvalvular atrial fibrillation","volume":"21","author":"Godino","year":"2020","journal-title":"J Cardiovasc Med"},{"key":"2025100705500383000_109.3.178.17","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s11606-020-05777-3","article-title":"Comparative safety and effectiveness of direct-acting oral anticoagulants versus warfarin: a national cohort study of nursing home residents","volume":"35","author":"Alcusky","year":"2020","journal-title":"J Gen Intern Med"},{"key":"2025100705500383000_109.3.178.18","first-page":"860","article-title":"Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: Part 2","volume":"38","author":"Diener","year":"2017","journal-title":"Eur Heart J"},{"key":"2025100705500383000_109.3.178.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12199-020-00862-9","article-title":"Body mass index, waist circumference, and risk of hearing loss: a meta-analysis and systematic review of observational study","volume":"25","author":"Yang","year":"2020","journal-title":"Environ Health Prev Med"},{"key":"2025100705500383000_109.3.178.20","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.amjmed.2019.01.025","article-title":"Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation","volume":"132","author":"Arbel","year":"2019","journal-title":"Am J Med"},{"key":"2025100705500383000_109.3.178.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12872-020-01340-4","article-title":"Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses","volume":"20","author":"Briasoulis","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"2025100705500383000_109.3.178.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.07.045"},{"key":"2025100705500383000_109.3.178.23","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.amjcard.2020.01.044","article-title":"Pattern and impact of off-label underdosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation who are indicated for standard dosing","volume":"125","author":"Cho","year":"2020","journal-title":"Am J Cardiol"},{"key":"2025100705500383000_109.3.178.24","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11239-019-01934-6","article-title":"Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings","volume":"48","author":"Ikeda","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"2025100705500383000_109.3.178.25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211766","article-title":"Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation","volume":"14","author":"Kim","year":"2019","journal-title":"PLoS One"},{"key":"2025100705500383000_109.3.178.26","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/europace\/eux247","article-title":"Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation","volume":"19","author":"Lee","year":"2017","journal-title":"Europace"},{"key":"2025100705500383000_109.3.178.27","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1161\/STROKEAHA.118.024210","article-title":"Optimal rivaroxaban dose in Asian patients with atrial fibrillation and normal or mildly impaired renal function","volume":"50","author":"Lee","year":"2019","journal-title":"Stroke"},{"key":"2025100705500383000_109.3.178.28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1253\/circj.CJ-18-0991","article-title":"Clinical outcomes of off-label dosing of direct oral anticoagulant therapy among Japanese patients with atrial fibrillation identified from the SAKURA AF registry","volume":"83","author":"Murata","year":"2019","journal-title":"Circ J"},{"key":"2025100705500383000_109.3.178.29","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/cpt.1952","article-title":"Stroke and bleeding risks in patients with atrial fibrillation treated with reduced apixaban dose: a real-life study","volume":"108","author":"Salameh","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2025100705500383000_109.3.178.30","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/FJC.0000000000000913","article-title":"Appropriateness of the direct oral anticoagulants dosing in the middle East Gulf region","volume":"77","author":"Anouassi","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025100705500383000_109.3.178.31","doi-asserted-by":"crossref","unstructured":"Atallah B , Alsolh S , El Nekidy W , et al . P281 factors influencing apixaban dosing in the middle East Gulf region. Eur Heart J 2020;41.doi:10.1093\/ehjci\/ehz872.101","DOI":"10.1093\/ehjci\/ehz872.101"},{"key":"2025100705500383000_109.3.178.32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40267-019-00696-8","article-title":"Prevalence and predictors of inappropriate apixaban dosing in patients with non-valvular atrial fibrillation at a large tertiary academic medical institution","volume":"36","author":"Badreldin","year":"2020","journal-title":"Drugs Ther Perspect"},{"key":"2025100705500383000_109.3.178.33","first-page":"3","article-title":"European Stroke Organisation Conference: Abstracts","volume":"3(1_suppl","author":"Bosque Varela","year":"2018","journal-title":"Eur Stroke J"},{"key":"2025100705500383000_109.3.178.34","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/clc.22949","article-title":"Initial apixaban dosing in patients with atrial fibrillation","volume":"41","author":"Buchholz","year":"2018","journal-title":"Clin Cardiol"},{"key":"2025100705500383000_109.3.178.35","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.clinthera.2020.04.008","article-title":"Misdosing of non-vitamin K antagonist oral anticoagulants in primary care","volume":"42","author":"Cardoso","year":"2020","journal-title":"Clin Ther"},{"key":"2025100705500383000_109.3.178.36","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/europace\/eux316","article-title":"Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA registry","volume":"20","author":"Ruiz Ortiz","year":"2018","journal-title":"Europace"},{"key":"2025100705500383000_109.3.178.37","doi-asserted-by":"crossref","unstructured":"Sabbag A , Klempfner R , Shlomo N , et al . P4020Use of novel oral anticoagulants in patients with atrial fibrillation and moderate to severe renal dysfunction: findings from a prospective national registry. Eur Heart J 2017;38.doi:10.1093\/eurheartj\/ehx504.P4020","DOI":"10.1093\/eurheartj\/ehx504.P4020"},{"key":"2025100705500383000_109.3.178.38","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.07.028","article-title":"The comparison of Inappropriate-low-doses use among 4 direct oral anticoagulants in patients with atrial fibrillation: from the database of a single-center registry","volume":"27","author":"Sato","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2025100705500383000_109.3.178.39","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00380-019-01457-3","article-title":"Creatinine clearance and inappropriate dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation","volume":"35","author":"Yagi","year":"2020","journal-title":"Heart Vessels"},{"key":"2025100705500383000_109.3.178.40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026645"},{"key":"2025100705500383000_109.3.178.41","unstructured":"Brabandt v . Anticoagulants in non-valvular atrial fibrillation; 2016."},{"key":"2025100705500383000_109.3.178.42","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40780-020-0157-z","article-title":"Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study","volume":"6","author":"Miyazaki","year":"2020","journal-title":"J Pharm Health Care Sci"},{"key":"2025100705500383000_109.3.178.43","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j510"},{"key":"2025100705500383000_109.3.178.44","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.amjmed.2020.12.022","article-title":"Long-term clinical outcomes of underdosed direct oral anticoagulants in patients with atrial fibrillation and atrial flutter","volume":"134","author":"Ashraf","year":"2021","journal-title":"Am J Med"},{"key":"2025100705500383000_109.3.178.45","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jacc.2020.12.053","article-title":"Randomized, double-blind comparison of half-dose versus full-dose edoxaban in 14,014 patients with atrial fibrillation","volume":"77","author":"Steffel","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025100705500383000_109.3.178.46","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euv312"},{"key":"2025100705500383000_109.3.178.47","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31829a33d1"},{"key":"2025100705500383000_109.3.178.48","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/clc.23586","article-title":"Effect of non-recommended doses versus recommended doses of direct oral anticoagulants in atrial fibrillation patients: a meta-analysis","volume":"44","author":"Liu","year":"2021","journal-title":"Clin Cardiol"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2022-321114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T12:50:19Z","timestamp":1759841419000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2022-321114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,1,11]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/heartjnl-2022-321114"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2022-321114","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]}}}